Patient group input submissions: Ixekizumab (Taltz) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or photothe...

Published 2017

CADTH Canadian Drug Expert Committee recommendation: Vedolizumab (Entyvio -- Takeda Canada Inc.) : indication : for the treatment of adult patients with moderately to severely acti...

Published 2020

CADTH Canadian Drug Expert Committee recommendation: Brolucizumab (Beovu -- Novartis Pharmaceuticals Canada Inc.) : indication : treatment of neovascular (wet) age-related macular...

Published 2020

CADTH Canadian drug expert committee recommendation: Burosumab (Crysvita -- Kyowa Kirin Limited) : indication : treatment of x-linked hypophosphatemia

Published 2020

CADTH Canadian Drug Expert Committee recommendation: Vedolizumab (Entyvio -- Takeda Canada Inc.) : indication : for the treatment of adult patients with moderately to severely acti...

Published 2020

Seasonal influenza immunization of health care workers for the prevention of influenza in patients : a review of the clinical effectiveness

by Seal, Kelsey, Spry, Carolyn
Published 2017

CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: ankylosing spondylitis

Published 2020

CADTH Canadian Drug Expert Committee recommendation: Brolucizumab (Beovu -- Novartis Pharmaceuticals Canada Inc.) : indication : treatment of neovascular (wet) age-related macular...

Published 2020

Masks for prevention of influenza transmission in acute and long-term care settings : a review of clinical effectiveness, cost-effectiveness and guidelines

by Marchand, Dave K., Argáez, Charlene
Published 2020

CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis

Published 2018

Immune checkpoint inhibitors for classical Hodgkin lymphoma in brentuximab vedotin-naïve patients : a review of clinical effectiveness, cost-effectiveness, and guidelines

by Williams, D., Gray, Casey, Picheca, Lory
Published 2019

CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: ankylosing spondylitis

Published 2020

CADTH reimbursement recommendation: Emicizumab (Hemlibra) : Hoffmann-La Roche Ltd.) : indication: bleeding prevention, hemophilia A (congenital factor VIII deficiency)

Published 2020

Clinical review report: Emicizumab (Hemlibra) : Hoffmann-La Roche Ltd. : indication: bleeding prevention, hemophilia A.

Published 2021

Pharmacoeconomic report: Emicizumab (Hemlibra) : Hoffman-La Roche Ltd. : indication: bleeding prevention, hemophilia A.

Published 2021

Biologics versus immunomodulators or antibiotics for the management of fistulizing Crohn's disease : a review of comparative clinical effectiveness and cost-effectiveness

by Young, Calvin, Campbell, Kaitryn
Published 2019

Immune checkpoint inhibitors for classical Hodgkin lymphoma in brentuximab vedotin-naïve patients : a review of clinical effectiveness, cost-effectiveness, and guidelines

by Williams, D., Gray, Casey, Picheca, Lory
Published 2019

Masks for prevention of influenza transmission in acute and long-term care settings : a review of clinical effectiveness, cost-effectiveness and guidelines

by Marchand, Dave K., Argáez, Charlene
Published 2020

CADTH Canadian Drug Expert Committee recommendation: Ofatumumab (Kesimpta -- Novartis Hharmaceuticals Canada Inc.) : indication : multiple sclerosis, relapsing-remitting

Published 2021

Pharmacoeconomic report: Satralizumab (Enspryng) : (Hoffmann-La Roche Limited) : indication : neuromyelitis optica spectrum disorder

Published 2021